CytomX Therapeutics, Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 144 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in CytomX Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CTMX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
CytomX Therapeutics stock price (NASDAQ: CTMX)Use our graph to track the performance of CTMX stocks over time.
CytomX Therapeutics shares at a glance
|Latest market close||$7.16|
|52-week range||$5.31 - $10.05|
|50-day moving average||$6.29|
|200-day moving average||$7.59|
|Wall St. target price||$12.94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.20|
Buy CytomX Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CytomX Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CytomX Therapeutics price performance over time
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||14.74%|
|3 months (2021-05-05)||-16.06%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
CytomX Therapeutics financials
|Revenue TTM||$66.7 million|
|Gross profit TTM||$100.4 million|
|Return on assets TTM||-8.82%|
|Return on equity TTM||-56.21%|
|Market capitalisation||$356.6 million|
TTM: trailing 12 months
Shorting CytomX Therapeutics shares
There are currently 6.6 million CytomX Therapeutics shares held short by investors – that's known as CytomX Therapeutics's "short interest". This figure is 0.2% up from 6.6 million last month.
There are a few different ways that this level of interest in shorting CytomX Therapeutics shares can be evaluated.
CytomX Therapeutics's "short interest ratio" (SIR)
CytomX Therapeutics's "short interest ratio" (SIR) is the quantity of CytomX Therapeutics shares currently shorted divided by the average quantity of CytomX Therapeutics shares traded daily (recently around 862198.18417639). CytomX Therapeutics's SIR currently stands at 7.71. In other words for every 100,000 CytomX Therapeutics shares traded daily on the market, roughly 7710 shares are currently held short.
However CytomX Therapeutics's short interest can also be evaluated against the total number of CytomX Therapeutics shares, or, against the total number of tradable CytomX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CytomX Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 CytomX Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1233% of the tradable shares (for every 100,000 tradable CytomX Therapeutics shares, roughly 123 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CytomX Therapeutics.
Find out more about how you can short CytomX Therapeutics stock.
CytomX Therapeutics share dividends
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
CytomX Therapeutics share price volatility
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $5.31 up to $10.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6855. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics overview
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, ImmunoGen, Inc.
CytomX Therapeutics in the news
Frequently asked questionsWhat percentage of CytomX Therapeutics is owned by insiders or institutions?
Currently 1.151% of CytomX Therapeutics shares are held by insiders and 86.048% by institutions. How many people work for CytomX Therapeutics?
Latest data suggests 144 work at CytomX Therapeutics. When does the fiscal year end for CytomX Therapeutics?
CytomX Therapeutics's fiscal year ends in December. Where is CytomX Therapeutics based?
CytomX Therapeutics's address is: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is CytomX Therapeutics's ISIN number?
CytomX Therapeutics's international securities identification number is: US23284F1057 What is CytomX Therapeutics's CUSIP number?
CytomX Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23284F105
More guides on Finder
How to buy Chobani stock when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.
How to buy Stronghold Digital Mining (SDIG) stock when it goes public
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
How to buy ROX Financial LP (ROXA) stock when it goes public
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
Ask an Expert